Filing Details
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) filed a Form 8-K with the Securities and Exchange Commission on October 28, 2026, disclosing a material event.
8k filedNASDAQ:ARQT
Arcutis Biotherapeutics, Inc. (ARQT) Reports Material Event to SEC
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) filed a Form 8-K with the Securities and Exchange Commission on October 28, 2026, disclosing a material event.
At publication ·
What changed
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Arcutis Biotherapeutics filed a Form 8-K on October 28, 2026, disclosing a material event that shareholders should know about.
- The company's stock trades at $31.45 with a market capitalization of $3.3 billion.
- Form 8-K filings report events such as leadership changes, material agreements, acquisitions, or asset sales between regular reports.
Market Context
Arcutis Biotherapeutics, Inc.'s stock currently trades at $31.45 with a market capitalization of $3.3B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Arcutis Biotherapeutics, Inc.'s stock.
All SEC filings for Arcutis Biotherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ARQT Stock Page
Frequently Asked Questions
Where can I read ARQT's SEC filings?
Browse all filings on our ARQT SEC filings page.
What types of SEC filings does Arcutis Biotherapeutics, Inc. file?
Public companies like Arcutis Biotherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.